Q4 Earnings Forecast for GPCR Issued By Leerink Partnrs

Structure Therapeutics Inc. (NASDAQ:GPCR) – Investment analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for shares of Structure Therapeutics in a research note issued to investors on Monday, March 3rd. Leerink Partnrs analyst D. Risinger expects that the company will earn $2.58 per share for the quarter. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($1.46) EPS and FY2028 earnings at ($1.53) EPS.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01.

Several other equities analysts also recently commented on the company. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective on the stock. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Finally, William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $22.57 on Wednesday. Structure Therapeutics has a fifty-two week low of $19.61 and a fifty-two week high of $62.74. The company has a market capitalization of $1.29 billion, a P/E ratio of -30.50 and a beta of -2.75. The company has a fifty day moving average of $26.22 and a 200 day moving average of $33.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GPCR. ANTIPODES PARTNERS Ltd raised its stake in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics in the 4th quarter worth about $34,000. FNY Investment Advisers LLC purchased a new stake in shares of Structure Therapeutics during the 4th quarter valued at about $40,000. Finally, Assetmark Inc. lifted its holdings in shares of Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after acquiring an additional 719 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.